1-20 of 166
Parameswaran Hari
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Results from a Phase 1/2 Study of Tandem, Bispecific Anti-CD20/Anti-CD19 (LV20.19) CAR T-Cells for Mantle Cell Lymphoma

Nirav N. Shah, Fateeha Furqan, Aniko Szabo, Jessica Neumann, Parameswaran Hari, Dina Schneider, Bryon Johnson, Mehdi Hamadani, Timothy S. Fenske
Journal: Blood
Blood (2022) 140 (Supplement 1): 9318–9319.
https://doi.org/10.1182/blood-2022-158695
Published: 2022
Journal Articles

Outcomes of MRD-Adapted Treatment Modulation in Patients with Newly Diagnosed Multiple Myeloma Receiving Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) and Autologous Transplantation: Extended Follow up of the Master Trial

Luciano J. Costa, Saurabh Chhabra, Eva Medvedova, Timothy Martin Schmidt, Bhagirathbhai Dholaria, Kelly N. Godby, Rebecca Silbermann, Susan Bal, Anita D'Souza, Smith Giri, James L. Omel, Parameswaran Hari, Natalie Callander, Binod Dhakal
Journal: Blood
Blood (2022) 140 (Supplement 1): 7275–7277.
https://doi.org/10.1182/blood-2022-156730
Published: 2022
Journal Articles

Association of Human Leukocyte Antigen Variants with Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma

Ben Massat, Gokul Pareek, Christopher Staffi Buradagunta, Bicky Thapa, Paul Auer, Binod Dhakal, Siegfried Janz, Parameswaran Hari, Jing Dong
Journal: Blood
Blood (2022) 140 (Supplement 1): 10063–10064.
https://doi.org/10.1182/blood-2022-160086
Published: 2022
Journal Articles

Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study on Baseline Characteristics and Clinical Outcomes in NEWLY Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous STEM Cell Transplantation, a Study Off 61,725 Patients from 629 Centers

Laurent Garderet, Luuk Gras, Linda Koster, Anita D'Souza, Noel Estrada-Merly, Parameswaran Hari, Wael Saber, Andrew J. Cowan, Minako Iida, Shinichiro Okamoto, Hiroyuki Takamatsu, Shohei Mizuno, Koji Kawamura, Yoshihisa Kodera, Nada Hamad, Bor-Sheng Ko, Christopher Liam, KIM Wah HO, A. Sim Goh, S. Keat Tan, Alaa M. Elhaddad, Ali Bazarbachi, Qamar un Nisa Chaudhry, Rozan Alfar, Mohamed-Amine Bekadja, Malek Benakli, Cristobal Augusto Frutos Ortiz, Eloisa Riva, Sebastian Galeano, Francisca Bass, Hira S. Mian, Arleigh McCurdy, Feng Rong Wang, Daniel Neumann, Mickey Koh, John A. Snowden, Stefan Schönland, Donal P. McLornan, Patrick John Hayden, Anna Sureda, Hildegard T. Greinix, Mahmoud Aljurf, Yoshiko Atsuta, Dietger Niederwieser
Journal: Blood
Blood (2022) 140 (Supplement 1): 4839–4842.
https://doi.org/10.1182/blood-2022-164619
Published: 2022
Journal Articles

8-Day Versus 12-Day Manufactured LV20.19 CAR T-Cells for B-Cell Non-Hodgkin Lymphoma

Nirav N. Shah, Fateeha Furqan, Aniko Szabo, Jessica Neumann, Walter L. Longo, Parameswaran Hari, Dina Schneider, Bryon Johnson, Timothy S. Fenske, Mehdi Hamadani
Journal: Blood
Blood (2022) 140 (Supplement 1): 7480–7481.
https://doi.org/10.1182/blood-2022-169119
Published: 2022
Journal Articles

Quadruplet Induction, Autologous Transplantation and Minimal Residual Disease Adapted Consolidation and Treatment Cessation in Older Adults ≥70y with Newly Diagnosed Multiple Myeloma: A Subgroup Analysis of the Master Trial

Smith Giri, Saurabh Chhabra, Eva Medvedova, Bhagirathbhai Dholaria, Timothy Martin Schmidt, Kelly N. Godby, Rebecca Silbermann, Binod Dhakal, Susan Bal, Anita D'Souza, Aric C. Hall, Pamela Hardwick, Jim Omel, Robert Frank Cornell, Natalie Callander, Parameswaran Hari, Luciano J. Costa
Journal: Blood
Blood (2022) 140 (Supplement 1): 4431–4433.
https://doi.org/10.1182/blood-2022-160381
Published: 2022
Journal Articles

International Differences in Baseline Characteristics and Practice Patterns in Patients with NEWLY Diagnosed Multiple Myeloma Undergoing Upfront Autologous STEM Cell Transplantation

Laurent Garderet, Luuk Gras, Linda Koster, Anita D'Souza, Noel Estrada-Merly, Parameswaran Hari, Wael Saber, Andrew J Cowan, Minako Iida, Shinichiro Okamoto, Hiroyuki Takamatsu, Shohei Mizuno, Koji Kawamura, Yoshihisa Kodera, Nada Hamad, Bor-Sheng Ko, Christopher Liam, Kim Wah Ho, A Sim Goh, S Keat Tan, Alaa M. Elhaddad, Ali Bazarbachi, Qamar un Nisa Chaudhry, Rozan Alfar, Mohamed-Amine Bekadja, Malek Benakli, Cristobal Augusto Frutos Ortiz, Eloisa Riva, Sebastian Galeano, Francisca Bass, Hira S Mian, Arleigh McCurdy, Feng Rong Wang, Daniel Neumann, Mickey Koh, John A Snowden, Stefan Schönland, Donal P. McLornan, Patrick John Hayden, Anna Sureda, Hildegard T. Greinix, Mahmoud Aljurf, Yoshiko Atsuta, Dietger Niederwieser
Journal: Blood
Blood (2022) 140 (Supplement 1): 5225–5227.
https://doi.org/10.1182/blood-2022-165010
Published: 2022
Journal Articles

Chimeric Antigen Receptor-T (CAR-T) Cell Therapy Targeting BCMA in Patients with Prior Allogeneic Transplantation (allo-HCT) in Relapsed and/or Refractory Multiple Myeloma (RRMM)

Lindsay Hammons, Shabi Haider, Marcelo C Pasquini, Saurabh Chhabra, Sabarinath Radhakrishnan, Anthony E. Zamora, Meera Mohan, Jing Dong, Siegfried Janz, Anita D'Souza, Parameswaran Hari, Binod Dhakal
Journal: Blood
Blood (2022) 140 (Supplement 1): 7215–7216.
https://doi.org/10.1182/blood-2022-165483
Published: 2022
Journal Articles

KarMMa-2 Cohort 2a: Efficacy and Safety of Idecabtagene Vicleucel in Clinical High-Risk Multiple Myeloma Patients with Early Relapse after Frontline Autologous Stem Cell Transplantation

Saad Usmani, Krina Patel, Parameswaran Hari, Jesus Berdeja, Melissa Alsina, Ravi Vij, Noopur Raje, Xavier Leleu, Madhav Dhodapkar, Ran Reshef, Anna Truppel-Hartmann, Debashree Basudhar, Ethan Thompson, Xirong Zheng, Revathi Ananthakrishnan, Chiara Greggio, Linda Favre-Kontula, Lars Sternas, Jesús San-Miguel
Journal: Blood
Blood (2022) 140 (Supplement 1): 875–877.
https://doi.org/10.1182/blood-2022-162469
Published: 2022
Journal Articles

Analysis of Transplant-Eligible Patients (Pts) Who Received Frontline Daratumumab (DARA)-Based Quadruplet Therapy for the Treatment of Newly Diagnosed Multiple Myeloma (NDMM) with High-Risk Cytogenetic Abnormalities (HRCA) in the Griffin and Master Studies

Natalie Callander, Rebecca Silbermann, Jonathan L. Kaufman, Kelly N. Godby, Jacob P Laubach, Timothy Martin Schmidt, Douglas W Sborov, Eva Medvedova, Brandi Reeves, Binod Dhakal, Cesar Rodriguez, Saurabh Chhabra, Ajai Chari, Susan Bal, Larry D. Anderson, Jr., Bhagirathbhai Dholaria, Nitya Nathwani, Parameswaran Hari, Nina Shah, Naresh Bumma, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M. Wildes, Robert Z. Orlowski, Ken H. Shain, Andrew J. Cowan, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S. Lin, Smith Giri, Luciano J. Costa, Paul G. Richardson, Saad Usmani, Peter M. Voorhees
Journal: Blood
Blood (2022) 140 (Supplement 1): 10144–10147.
https://doi.org/10.1182/blood-2022-160451
Published: 2022
Journal Articles

Biologic Basis of the Impact of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma Treated with Quadruplet Therapy

Susan Bal, Saurabh Chhabra, Natalie S. Callander, Eva Medvedova, Bhagirathbhai Dholaria, Rebecca W. Silbermann, Kelly N. Godby, Binod Dhakal, Smith Giri, Anita d'Souza, Timothy M. Schmidt, Aric C. Hall, Pamela Hardwick, Robert F. Cornell, Parameswaran Hari, Luciano J. Costa
Journal: Blood
Blood (2021) 138 (Supplement 1): 483.
https://doi.org/10.1182/blood-2021-145533
Published: 2021
Journal Articles

Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), Autologous Transplantation and MRD Response-Adapted Consolidation and Treatment Cessation. Final Primary Endpoint Analysis of the Master Trial

Luciano J. Costa, Saurabh Chhabra, Natalie S. Callander, Eva Medvedova, Bhagirathbhai Dholaria, Rebecca W. Silbermann, Kelly N. Godby, Binod Dhakal, Susan Bal, Smith Giri, Anita d'Souza, Timothy M. Schmidt, Aric C. Hall, Pamela Hardwick, Robert F. Cornell, Parameswaran Hari
Journal: Blood
Blood (2021) 138 (Supplement 1): 481.
https://doi.org/10.1182/blood-2021-145494
Published: 2021
Journal Articles

Phase 1/2 Trial of IL7/IL15-Expanded Bispecific LV20.19 CAR T-Cells for Relapsed, Refractory B-Cell Non-Hodgkin Lymphoma

Nirav N. Shah, Joanna C. Zurko, Dina Schneider, Sharon Yim, Mehdi Hamadani, Timothy S. Fenske, Bryon Johnson, Parameswaran Hari
Journal: Blood
Blood (2021) 138 (Supplement 1): 95.
https://doi.org/10.1182/blood-2021-146638
Published: 2021
Journal Articles

Bispecific LV20.19 CAR T-Cells Expanded in IL-7 and IL-15 Have Greater Polyfunctionality and Polyfunctional Strength Than CAR T-Cells Expanded in IL-2

Joanna C. Zurko, Huiqing Xu, Katherine Chaney, Timothy S. Fenske, Mehdi Hamadani, Dina Schneider, Parameswaran Hari, Bryon Johnson, Nirav N. Shah
Journal: Blood
Blood (2021) 138 (Supplement 1): 1728.
https://doi.org/10.1182/blood-2021-146882
Published: 2021
Journal Articles

Manufacturing Bispecific LV20.19 CAR T-Cells with IL-7 & IL-15 for a Shorter Duration Improves CAR T-Cell Immunophenotype While Maintaining Target Cell Dose

Joanna C. Zurko, Katherine Chaney, Huiqing Xu, Dina Schneider, Parameswaran Hari, Bryon Johnson, Nirav N. Shah
Journal: Blood
Blood (2021) 138 (Supplement 1): 3883.
https://doi.org/10.1182/blood-2021-147405
Published: 2021
Journal Articles

Efficacy and Safety of Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 Subgroup Analysis

Andrzej Jakubowiak, Saad Z. Usmani, Jesus G. Berdeja, Mounzer Agha, Adam D Cohen, Parameswaran Hari, Jordan M. Schecter, Deepu Madduri, Tzu-Min Yeh, Yunsi Olyslager, Arnob Banerjee, Carolyn C. Jackson, Alicia Allred, Enrique Zudaire, William Deraedt, Changwei Zhou, Dong Geng, Lida Pacaud, Yi Lin, Thomas Martin, Sundar Jagannath
Journal: Blood
Blood (2021) 138 (Supplement 1): 3938.
https://doi.org/10.1182/blood-2021-146069
Published: 2021
Journal Articles

Risk of Infections with BCMA-Directed Immunotherapy in Multiple Myeloma

Meera Mohan, Sneha Nagavally, Binod Dhakal, Saurabh Chhabra, Anita D'Souza, Parameswaran Hari
Journal: Blood
Blood (2021) 138 (Supplement 1): 1626.
https://doi.org/10.1182/blood-2021-148223
Published: 2021
Journal Articles

Efficacy of Treatments for Patients with Triple-Class Refractory (TCR) Multiple Myeloma (MM): Benchmark for New Agents Utilizing Real-World Data (RWD)

Luciano J. Costa, Robert Frank Cornell, Natalie S. Callander, Saurabh Chhabra, Michaela Liedtke, Ankit Kansagra, Kelly N. Godby, Susan Bal, Smith Giri, Ehsan Malek, Yubin Kang, Ravi Vij, Saad Z. Usmani, Parameswaran Hari, Shaji Kumar
Journal: Blood
Blood (2021) 138 (Supplement 1): 3786.
https://doi.org/10.1182/blood-2021-144387
Published: 2021
Journal Articles

Exploring Interest in and Feasibility of a Lifestyle Intervention for Multiple Myeloma Patients

Abigail Kerschner, Allen Hodge, Alexis Williams, Patrica Sheean, Kathleen Jensik, Alexis Visotcky, Parameswaran Hari, Meera Mohan, Saurabh Chhabra, Anita D'Souza, Melinda Stolley
Journal: Blood
Blood (2021) 138 (Supplement 1): 4018.
https://doi.org/10.1182/blood-2021-148134
Published: 2021
Journal Articles

Updated Results from CARTITUDE-1: Phase 1b/2Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma

Thomas Martin, Saad Z. Usmani, Jesús G. Berdeja, Andrzej Jakubowiak, Mounzer Agha, Adam D Cohen, Parameswaran Hari, David Avigan, Abhinav Deol, Myo Htut, Alexander Lesokhin, Nikhil C. Munshi, Elizabeth O'Donnell, A. Keith Stewart, Jordan M. Schecter, Jenna D. Goldberg, Carolyn C. Jackson, Tzu-Min Yeh, Arnob Banerjee, Alicia Allred, Enrique Zudaire, William Deraedt, Deepu Madduri, Yunsi Olyslager, Changwei Zhou, Lida Pacaud, Yi Lin, Sundar Jagannath
Journal: Blood
Blood (2021) 138 (Supplement 1): 549.
https://doi.org/10.1182/blood-2021-146060
Published: 2021